Tumors induce immune tolerance through activation of β-catenin/TCF4 signaling in dendritic cells: A novel therapeutic target for cancer immunotherapy

Amol Suryawanshi, Santhakumar Manicassamy

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Tumors promote immune suppression and dendritic cells (DCs) play a key role in this. However, signaling networks that program DCs to induce immune suppression are unknown. In our recent study, we showed that tumors activate β-catenin/TCF4 in DCs programming them to a regulatory state, which promotes T regulatory responses while suppresses effector T cell responses. Thus, targeting DCs-β-catenin pathway represents a promising target for anticancer immunotherapy.

Original languageEnglish (US)
JournalOncoImmunology
Volume4
Issue number12
DOIs
StatePublished - Dec 2 2015

Fingerprint

Catenins
Immune Tolerance
Immunotherapy
Dendritic Cells
Neoplasms
Therapeutics
T-Lymphocytes

Keywords

  • Wnt
  • cancer immunotherapy
  • dendritic cells
  • immune suppression
  • regulatory T cells
  • retionic acid
  • β-catenin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

@article{2ec8e1daeea54190af6b493580df5a2f,
title = "Tumors induce immune tolerance through activation of β-catenin/TCF4 signaling in dendritic cells: A novel therapeutic target for cancer immunotherapy",
abstract = "Tumors promote immune suppression and dendritic cells (DCs) play a key role in this. However, signaling networks that program DCs to induce immune suppression are unknown. In our recent study, we showed that tumors activate β-catenin/TCF4 in DCs programming them to a regulatory state, which promotes T regulatory responses while suppresses effector T cell responses. Thus, targeting DCs-β-catenin pathway represents a promising target for anticancer immunotherapy.",
keywords = "Wnt, cancer immunotherapy, dendritic cells, immune suppression, regulatory T cells, retionic acid, β-catenin",
author = "Amol Suryawanshi and Santhakumar Manicassamy",
year = "2015",
month = "12",
day = "2",
doi = "10.1080/2162402X.2015.1052932",
language = "English (US)",
volume = "4",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "12",

}

TY - JOUR

T1 - Tumors induce immune tolerance through activation of β-catenin/TCF4 signaling in dendritic cells

T2 - A novel therapeutic target for cancer immunotherapy

AU - Suryawanshi, Amol

AU - Manicassamy, Santhakumar

PY - 2015/12/2

Y1 - 2015/12/2

N2 - Tumors promote immune suppression and dendritic cells (DCs) play a key role in this. However, signaling networks that program DCs to induce immune suppression are unknown. In our recent study, we showed that tumors activate β-catenin/TCF4 in DCs programming them to a regulatory state, which promotes T regulatory responses while suppresses effector T cell responses. Thus, targeting DCs-β-catenin pathway represents a promising target for anticancer immunotherapy.

AB - Tumors promote immune suppression and dendritic cells (DCs) play a key role in this. However, signaling networks that program DCs to induce immune suppression are unknown. In our recent study, we showed that tumors activate β-catenin/TCF4 in DCs programming them to a regulatory state, which promotes T regulatory responses while suppresses effector T cell responses. Thus, targeting DCs-β-catenin pathway represents a promising target for anticancer immunotherapy.

KW - Wnt

KW - cancer immunotherapy

KW - dendritic cells

KW - immune suppression

KW - regulatory T cells

KW - retionic acid

KW - β-catenin

UR - http://www.scopus.com/inward/record.url?scp=84944613895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944613895&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1052932

DO - 10.1080/2162402X.2015.1052932

M3 - Article

AN - SCOPUS:84944613895

VL - 4

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 12

ER -